Key result
The everolimus-eluting Xience V stent has been extensively evaluated in the SPIRIT clinical trial program to improve the efficacy and safety of stent implantation.
This review summarizes the SPIRIT clinical trial program evaluating the everolimus-eluting Xience V stent and its impact on clinical practice.
Answers are grounded in this paper and cite their sources.
Supports Xience V in PCI; leaves open need for updated head-to-head trials with contemporary platforms.
Percutaneous coronary angioplasty started a revolution by providing a mechanical means of relieving angina. Abrupt vessel closure and restenosis emerged as its major limitations. Bare-metal stents dramatically reduced acute vessel closure, but restenosis, although significantly reduced, remained a clinical problem. Drug-eluting stents mitigated the problem of restenosis to a large extent. However, a small but significant increase in very-late stent thrombosis rates have been noted. Newer stents have been introduced in order to improve the efficacy and safety of stent implantation. The everolimus-eluting Xience V™ stent has been extensively evaluated in the SPIRIT clinical trial program. This article summarizes the various studies of this program and their impact on clinical practice.
No takes yet. Share an insight, caveat, or question.
Kaul et al. (2010) conducted a review in Coronary artery disease. Everolimus-eluting Xience V stent was evaluated. The everolimus-eluting Xience V stent has been extensively evaluated in the SPIRIT clinical trial program to improve the efficacy and safety of stent implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: